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Sarcomas, including rhabdomyosarcoma (RMS), are rarely
encountered in effusion specimens; therefore, difficulties in the
accurate diagnosis of metastatic sarcomas in effusions can occa-
sionally arise. Immunohistochemistry for myogenin has emerged
as a useful adjunct in the diagnosis of RMS, especially in small
biopsy specimens. To date, there are no published series
describing the utility of immunocytochemistry for myogenin in
the diagnosis of RMS in effusion specimens. A total of 15
patients, for whom metastatic sarcomas were diagnosed in effu-
sion specimens between 1998 and 2012, were identified for
analysis: alveolar RMS (n5 5); embryonal RMS (n5 1); pleo-
morphic RMS (n5 1); angiosarcoma (n5 1); Ewing’s sarcoma
(n5 2); osteosarcoma (n5 1); endometrial stromal sarcoma
(n5 1); unclassified spindle cell sarcoma (n5 1); unclassified/
undifferentiated pleomorphic sarcoma (n5 1); and leiomyosar-
coma (n5 1). Immunocytochemistry for myogenin was per-
formed for each of these cases as well as for 102 effusions that
were positive for metastatic carcinoma. Immunocytochemistry
for myogenin diffusely and strongly highlighted the nuclei of the
tumor cells in six (86%) of seven cases of metastatic RMS; spe-
cifically, the five alveolar RMS and one embryonal RMS cases.
The one case of pleomorphic RMS, the eight remaining meta-
static sarcoma cases, and all 102 cases of metastatic carcinoma
were completely negative for myogenin expression. In conclu-
sion, immunocytochemistry for myogenin is a sensitive and spe-
cific ancillary adjunct in the diagnostic evaluation of metastatic
RMS in effusion specimens. Diagn. Cytopathol. 2013;41:955–
959. VC 2013 Wiley Periodicals, Inc.
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Rhabdomyosarcoma (RMS) is an aggressive sarcoma with
skeletal-muscle differentiation that primarily affects chil-
dren and young adults and involves the head/neck,
extremities, and soft tissues. Rarely, RMS can exfoliate
into body fluids resulting in malignant effusions.1–4
Histologic subtypes of RMS include embryonal, alveolar,
and pleomorphic RMS. Diagnosis of RMS is based on a
combination of histologic findings in surgical biopsies or
resections along with ancillary studies including immuno-
histochemistry and cytogenetics. With respect to the for-
mer, the clinical utilization of muscle markers such as
desmin and myogenin has emerged as valuable adjuncts
in the diagnostic confirmation of RMS. As desmin
expression is not specific for RMS, myogenin has
emerged as a sensitive and specific marker of skeletal
muscle differentiation.5–7
Myogenin is one of several basic helix-loop-helix myo-
genic transcription factors, including MyoD, Myf5, and
MRF4 that play critical roles in skeletal muscle differen-
tiation and development during embryogenesis.8 Previous
studies of myogenin expression in RMS have cited a sen-
sitivity of 71–100% and high specificity with regards to
spindle cell neoplasms.5,7 The extent of nuclear immuno-
reactivity in RMS varies depending on the subtype of
RMS being examined. For instance, Morgenstern et al.
demonstrated that the percentage of myogenin-positive
cells is greater in alveolar RMS when compared to
embryonal RMS.7
Effusions that are positive for metastatic sarcoma are
uncommon and account for up to 5% of malignant effu-
sions.9 The utility of myogenin immunocytochemistry is
therefore of particular interest for the diagnosis of RMS
in effusion specimens as the cytomorphologic distinction
between RMS and its mimics including reactive mesothe-
lium, metastatic carcinoma, and other sarcomas can be
challenging.2,4 In addition, the diagnostic utility of des-
min is limited as benign mesothelial cells in the back-
ground will also exhibit immunoreactivity for desmin.10
Although immunohistochemistry for myogenin has been
thoroughly studied in biopsies and surgical resection
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specimens, reports in the literature regarding the efficacy
of myogenin immunocytochemistry in the diagnosis of
RMS in cytology specimens, especially effusions, are
sparse and primarily limited to case reports.2–4,11 There-
fore, in this study, we sought to examine a series of meta-
static RMS in effusions, especially focusing on the
diagnostic utility of immunocytochemistry for myogenin
expression.
Materials and Methods
The study was approved by the Institutional Review
Board at the University of Michigan. The electronic pa-
thology database was searched to identify cases of meta-
static sarcoma diagnosed between 1998 and 2012 (Table
I). Fifteen patients for whom metastatic sarcomas were
diagnosed in effusion specimens were identified for anal-
ysis: alveolar RMS (n5 5); embryonal RMS (n5 1);
pleomorphic RMS (n5 1); angiosarcoma (n5 1);
Ewing’s sarcoma (n5 2); pleomorphic extraskeletal os-
teosarcoma (n5 1); endometrial stromal sarcoma
(n5 1); unclassified spindle cell sarcoma (n5 1); unclas-
sified/undifferentiated pleomorphic sarcoma (n5 1); and
leiomyosarcoma (n5 1). For the five patients with alveo-
lar RMS, the right arm, peritoneum, retroperitoneum,
prostate, and left hand represented the primary sites. The
locations of the primary tumors for the embryonal and
pleomorphic RMS patients were the mediastinum and
left spermatic cord, respectively. The diagnoses of the
primary RMS tumors were rendered based on histomor-
phologic features and confirmatory immunohistochemis-
try for desmin and myogenin. Desmin immunoreactivity
was observed for all seven RMS cases. Myogenin immu-
nohistochemistry was positive in the tumor cells for the
five alveolar RMS and one embryonal RMS primaries.
Confirmatory molecular studies were performed on the
primary RMS tumors in two alveolar RMS cases; a
FOXO1 gene rearrangement was detected via fluores-
cence in situ hybridization in one case and via reverse
transcriptase-polymerase chain reaction in another case.
Molecular studies were not performed for the other five
RMS primary tumors. Next, the primary sites for the
angiosarcoma, osteosarcoma, unclassified spindle cell
sarcoma, and unclassified/undifferentiated pleomorphic
sarcoma patients were the pericardium, retroperitoneum,
right foot, and abdomen, respectively. The uterus repre-
sented the primary sites for the endometrial stromal
sarcoma and leiomyosarcoma cases. For the two patients
with Ewing’s sarcoma, the left fibula and left pelvis
represented the primary sites.
In addition, 102 effusion cases that were positive for
metastatic carcinoma were also collected for analysis (Ta-
ble I). Primary sites for the metastatic carcinomas were as
follows: M€ullerian (n5 35); lung (n5 28); breast
(n5 18); gastroesophageal (n5 9); pancreaticobiliary
(n5 8); and, colorectal (n5 4). Cell blocks were retrieved
and the hematoxylin and eosin (H&E) stained sections
were examined to confirm the presence of tumor cells in
the cell blocks.
Immunocytochemistry for myogenin was performed for
each of the above cases. Immunostaining was performed
on the DAKO Autostainer (DAKO, Carpinteria, CA)
using DAKO LSAB1 and diaminobenzadine as the
chromogen. De-paraffinized sections of formalin-fixed tis-
sue at 5-mm thickness were labeled with a mouse mono-
clonal antibody directed against myogenin (clone F5D,
1:50 dilution; DAKO, Carpinteria, CA). Appropriate neg-
ative (immunostaining with the primary antibody omitted)
and positive controls (tissue sections of known RMS
tumors) were stained in parallel. Tumor cells and back-
ground mesothelial cells and inflammatory cells were
scored for nuclear myogenin immunoreactivity in each
case.
Results
A total of seven cases of metastatic RMS diagnosed in
effusion specimens were examined in this study: five
alveolar RMS; one embryonal RMS, and one pleomorphic
RMS (Fig. 1). The tumor cells in all five alveolar RMS
cases exhibited a predominantly discohesive pattern of
small, round blue cells with moderate to high nuclear-to-
cytoplasmic ratios (Fig. 1A). In cells with moderate
amounts of cytoplasm, the nuclei were eccentrically
placed. Occasional small, tight clusters were appreciated.
The chromatin within the nuclei was granular in texture.
Table I. Cases Examined for Myogenin Expression by
Immunocytochemistry
Malignancy (n)
# Myogenin-
positive (%)
Rhabdomyosarcoma (n5 7) 6 (86%)
Alveolar rhabdomyosarcoma (n5 5) 5 (100%)
Embryonal rhabdomyosarcoma (n5 1) 1 (100%)
Pleomorphic rhabdomyosarcoma (n5 1) 0 (0%)
Sarcoma, non-rhabdomyosarcoma (n5 8) 0 (0%)
Angiosarcoma (n5 1) 0 (0%)
Ewing’s sarcoma (n5 2) 0 (0%)
Osteosarcoma (n5 1) 0 (0%)
Endometrial stromal sarcoma (n5 1) 0 (0%)
Unclassified spindle cell sarcoma (n5 1) 0 (0%)
Unclassified/undifferentiated
pleomorphic sarcoma (n5 1)
0 (0%)
Leiomyosarcoma (n5 1) 0 (0%)
Carcinoma (n5 102) 0 (0%)
Mullerian (n5 35) 0 (0%)
Lung (n5 28) 0 (0%)
Breast (n5 18) 0 (0%)
Gastroesophageal (n5 9) 0 (0%)
Pancreaticobiliary (n5 8) 0 (0%)
Colorectal (n5 4) 0 (0%)
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Small but conspicuous nucleoli were evident in four of
five cases. Multinucleated cells were present but few in
number in all five cases. The one case of embryonal
RMS was hypocellular but significant for the presence of
single neoplastic cells with scant to moderate amounts of
cytoplasm (Fig. 1B). Nuclei were eccentrically placed in
cells exhibiting moderate amounts of cytoplasm. The
chromatin texture was granular and small, conspicuous
nucleoli were present. Multinucleated cells and tumor cell
clusters were not evident in this case. The tumor cells for
the one case of pleomorphic RMS were markedly
enlarged with moderate to abundant cytoplasm, contained
eccentrically placed nuclei, and were present in a discohe-
sive pattern. Multinucleation and prominent macronu-
cleoli were frequently encountered (Fig. 1C).
Immunocytochemistry for myogenin diffusely and
strongly highlighted the nuclei of the tumor cells in six
(86%) of seven cases of metastatic RMS; specifically, the
five alveolar RMS cases and the one case of embryonal
RMS (Figs. 2A–D). The one case of pleomorphic RMS
was completely negative for myogenin expression (Figs.
2E–F). To determine the specificity of myogenin immu-
nocytochemistry for the detection of metastatic RMS in
effusion specimens, eight cases of non-RMS metastatic
sarcoma effusion specimens were also examined for myo-
genin expression. These metastases were from primary
sarcomas originally diagnosed as: angiosarcoma (n5 1);
Ewing’s sarcoma (n5 2); osteosarcoma (n5 1); endome-
trial stromal sarcoma (n5 1); unclassified spindle cell sar-
coma (n5 1); unclassified/undifferentiated pleomorphic
sarcoma (n5 1); and leiomyosarcoma (n5 1). None of
these cases exhibited immunoreactivity for myogenin in
the tumor cells. To further investigate the specificity of
myogenin immunocytochemistry, 102 cases of metastatic
carcinoma were analyzed for myogenin expression as
negative controls. The tumor cells in all 102 cases were
myogenin-negative (Table I). Immunoreactivity for
myogenin in background mesothelial cells and inflamma-
tory cells was not observed in any instances.
Discussion
The literature on the cytologic diagnosis of RMS in effu-
sion specimens is sparse and limited to case reports
owing to the rarity of metastatic RMS presenting in body
fluids.2–4 These case reports all focused on cases of meta-
static alveolar RMS. This in addition to the difficulty in
distinguishing RMS from background mesothelial cells
and inflammatory cells as well as other metastatic neo-
plasms contribute to difficulties in accurately diagnosing
metastatic RMS in effusions. The accurate diagnosis is
essential for timely, appropriate management in patients
afflicted with these aggressive tumors. In tissue speci-
mens, myogenin immunohistochemistry has been shown
to be a sensitive and specific marker for RMS.5–7,12 How-
ever, the current knowledge regarding the utility of this
marker in effusion cytology is limited.
Although the cytologic features of alveolar RMS have
not been extensively described in effusion specimens, two
cytomorphologically distinct types of RMS cells have
been described in fine-needle aspiration and small biopsy
specimens: (1) small, round blue cells with scant
cytoplasm and hyperchromatic nuclei and (2) differenti-
ated rhabdomyoblasts with eosinophilic cytoplasm, some
exhibiting prominent cytoplasmic cross-striations.13,14 The
former cell type is more commonly encountered in
effusion specimens2–4; our cytomorphologic observations
corroborate this notion. Nelson et al.2 reported a case of
metastatic alveolar RMS in an ascites specimen that was
composed of the former cell type that was initially misin-
terpreted as reactive mesothelial cells. Further workup
revealed the presence of neoplastic cells that exhibited
immunoreactivity for myogenin ultimately leading to a di-
agnosis of metastatic RMS. Two additional case reports
describe pleural effusion specimens with cytologically
Fig. 1. Cytomorphologic features of metastatic alveolar, embryonal, and pleomorphic rhabdomyosarcoma (RMS) in effusion specimens. Representative
photomicrographs obtained from Papanicolaou-stained slides prepared from cases of (A) alveolar, (B) embryonal, and (C) pleomorphic RMS are
shown. All photomicrographs were obtained at 10003 magnification. [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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suspicious cells that exhibited nuclear immunoreactivity
for myogenin thereby confirming a diagnosis of meta-
static RMS.3,4
The results of our study, which examine a series of
RMS cases, corroborate the findings in the aforemen-
tioned case reports. All five of our alveolar RMS cases
exhibited diffuse, strong, nuclear immunoreactivity for
myogenin in the tumor cells. In addition, despite previous
studies reporting patchy immunoreactivity for myogenin
in embryonal RMS,6,7 we observed diffuse immunoreac-
tivity for this marker in our one case of metastatic embry-
onal RMS. Next, myogenin immunoreactivity was not
detected in the tumor cells in our one case of metastatic
pleomorphic RMS. In this patient, the spermatic cord rep-
resented the primary site; this site has been recognized as
a site within which this tumor can arise.15 Prior immuno-
histochemical workup revealed that the tumor cells in this
resection specimen were negative for cytokeratins but
positive for desmin. The cytomorphology of the tumor
cells in this effusion specimen was identical to that in
the primary resection specimen. We retrospectively per-
formed immunohistochemistry for myogenin on this spec-
imen. Similar to the findings in the effusion specimen, we
observed that none of the tumor cells exhibited immuno-
reactivity for this marker. Of note, Furlong and colleagues
observed that 44% of pleomorphic RMS are negative for
myogenin expression on immunohistochemistry.15
Overall, we observed a sensitivity of 86% for myogenin
immunocytochemistry in the detection of RMS tumor cells
in effusion specimens. Next, we sought to examine the
specificity of this marker in exfoliative fluid cytology. We
approached this issue by performing immunocytochemistry
on eight malignant effusion cases of metastatic sarcoma
other than RMS. None of the tumor cells in these eight
Fig. 2. Immunocytochemistry for myogenin in effusion specimens positive for metastatic rhabdomyosarcoma (RMS). (A, C, and E) Representative
photomicrographs obtained from H&E stained cell block sections derived from cases of alveolar, embryonal, and pleomorphic RMS, respectively. (B,
D, and F) Corresponding immunohistochemical stains for myogenin expression for the cases of alveolar, embryonal, and pleomorphic RMS, respec-
tively. The tumor cells in the cases of alveolar and embryonal RMS are positive for myogenin expression whereas the one case of pleomorphic RMS
is negative for myogenin expression. All photomicrographs were obtained at 6003 magnification. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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cases exhibited myogenin immunoreactivity. As reactive
mesothelial cells and metastatic carcinomas can occasion-
ally mimic RMS, we also tested 102 cases of carcinoma-
tous effusions. Again, immunocytochemistry for myogenin
was completely negative in all of these cases. Of note, im-
munostaining for desmin, in addition to myogenin, is also
used to confirm myogenic differentiation in RMS. In effu-
sion specimens, desmin immunocytochemistry is of limited
value; desmin immunostains are difficult to interpret in this
setting as background mesothelial cells exhibit immunore-
activity for desmin.10,16 In our study, we did not observe
any immunoreactivity for myogenin in the background me-
sothelial cell population.
The limited number of effusion cases with metastatic
sarcoma, including RMS, represents a limitation to this
study. This is expected as metastatic sarcoma is rarely
encountered in body fluids, compared to reactive and
carcinomatous effusions. Nonetheless, our study demon-
strates that careful cytomorphologic evaluation with
adjunct immunocytochemistry for myogenin can accu-
rately diagnose metastatic RMS in effusion specimens.
Myogenin represents a sensitive and specific marker for
the workup of RMS in effusion cytology.
References
1. Longatto-Filho A, Bisi H, Bortolan J, Granja NV, Lombardo V.
Cytologic diagnosis of metastatic sarcoma in effusions. Acta Cytol
2003;47:317–318.
2. Nelson AC, Singh C, Pambuccian SE. Cytological diagnosis of meta-
static alveolar rhabdomyosarcoma in the ascitic fluid: Report of a
case highlighting the diagnostic difficulties. Cytojournal 2012;9:9.
3. Theunissen P, Cremers M, van der Meer S, Bot F, Bras J. Cyto-
logic diagnosis of rhabdomyosarcoma in a child with a pleural effu-
sion. A case report. Acta cytol 2004;48:249–253.
4. Thiryayi SA, Rana DN, Roulson J, Crosbie P, Woodhead M, Eyden
BP, et al. Diagnosis of alveolar rhabdomyosarcoma in effusion cy-
tology: A diagnostic pitfall. Cytopathology 2010;21:273–275.
5. Cessna MH, Zhou H, Perkins SL, Tripp SR, Layfield L, Daines C,
et al. Are myogenin and myoD1 expression specific for
rhabdomyosarcoma? A study of 150 cases, with emphasis on spin-
dle cell mimics. Am J Surg Pathol 2001;25:1150–1157.
6. Kumar S, Perlman E, Harris CA, Raffeld M, Tsokos M. Myogenin
is a specific marker for rhabdomyosarcoma: An immunohistochemi-
cal study in paraffin-embedded tissues. Mod Pathol 2000;13:988–
993.
7. Morgenstern DA, Rees H, Sebire NJ, Shipley J, Anderson J. Rhab-
domyosarcoma subtyping by immunohistochemical assessment of
myogenin: tissue array study and review of the literature. Pathol
Oncol Res 2008;14:233–238.
8. Berkes CA, Tapscott SJ. MyoD and the transcriptional control of
myogenesis. Semin Cell Dev Biol 2005;16:585–595.
9. Chivukula M, Saad R. Metastatic sarcomas, melanoma, and other
non-epithelial neoplasms. In: Shidham VB, Atkinson BF, editors.
Cytopathologic diagnosis of serous fluids. Philadelphia: Elsevier
Saunders; 2007. p 147–156.
10. Hasteh F, Lin GY, Weidner N, Michael CW. The use of immuno-
histochemistry to distinguish reactive mesothelial cells from malig-
nant mesothelioma in cytologic effusions. Cancer Cytopathol
2010;118:90–96.
11. Kishore B, Khare P, Gupta RJ, Gupta C, Khare V. A rare case of
paratesticular pleomorphic rhabdomyosarcoma diagnosed by
fine needle aspiration: A case report. Diagn Cytopathol 2010;38:
121–126.
12. Hostein I, Andraud-Fregeville M, Guillou L, Terrier-Lacombe MJ,
Deminiere C, Ranchere D, et al. Rhabdomyosarcoma: Value of
myogenin expression analysis and molecular testing in diagnosing
the alveolar subtype. An analysis of 109 paraffin-embedded speci-
mens. Cancer 2004;101:2817–2824.
13. Castelino-Prabhu S, Ali SZ. “Strap cells” in primary prostatic rhab-
domyosarcoma in a child. Diagn Cytopathol 2010;38:505–506.
14. Klijanienko J, Caillaud JM, Orbach D, Brisse H, Lagace R, Sastre-
Gareau X. Cyto-histological correlations in primary, recurrent, and
metastatic bone and soft tissue osteosarcoma. Institut Curie’s expe-
rience. Diagn Cytopathol 2007;35:270–275.
15. Furlong MA, Mentzel T, Fanburg-Smith JC. Pleomorphic rhabdo-
myosarcoma in adults: a clinicopathologic study of 38 cases with
emphasis on morphologic variants and recent skeletal muscle-spe-
cific markers. Mod Pathol 2001;14:595–603.
16. Afify AM, Al-Khafaji BM, Paulino AF, Davila RM. Diagnostic use
of muscle markers in the cytologic evaluation of serous fluids. Appl
Immunihistochem Mol Morphol 2002;10:178–182.
Diagnostic Cytopathology DOI 10.1002/dc
RHABDOMYOSARCOMA IN EFFUSIONS
Diagnostic Cytopathology, Vol. 41, No 11 959
